RSV Webinar Series Programme

Return to RSV Webinar Series home page

RSV WEBINAR SERIES February 2021

PROGRAMME

1 February Epidemiology and Spectrum of RSV Disease

3pm (GMT) Chair: Dr Natasha Halasa, Vanderbilt University Medical Center, USA

VIEW WEBINAR RECORDING

Keynote Presentation:

RSV Epidemiology in a Changing World

Prof Harish Nair

Chair of Paediatric Infectious Diseases and Global Health

Centre for Global Health, Usher Institute
The University of Edinburgh, UK

(30 min presentation - includes 5 min for Q&A)

The impact of respiratory syncytial virus (RSV) on mortality and hospitalizations in Hong Kong, 1998-2015

Xiong Qian | University of Hong Kong, Hong Kong (15min)

Early life severe respiratory syncytial virus infection increased the risk of asthma later in life Maarten van Wijhe | Statens Serum Institut, Denmark (15min)

The Clinical Characteristics, Severity, and Seasonality of RSV Subtypes among Hospitalized Jordanian Children

Ahmad Yanis | Vanderbilt University Medical Center, Nashville, USA (15min)

Maternal and family social risk factors for early life respiratory syncytial virus (RSV)-related hospitalizations

Tiffany Fitzpatrick | Yale School of Public Health, New Haven, USA (15min)

8 February RSV Molecular Biology

3pm (GMT) Chair: Prof Ultan Power, Queens University Belfast, UK

VIEW WEBINAR RECORDING

Keynote Presentation:

Insights into the generation and function of defective viral genomes during RSV infection

Prof Carolina Lopez

BJC Investigator / Lopez Lab

Department of Molecular Biology
Washington University School of Medicine in St. Louis, USA

(30 min presentation - includes 5 min for Q&A)

Optimized reverse genetics systems for clinical isolates of respiratory syncytial virus ON1 and BA9 strains enables rapid evaluation of naturally occurring antibody escape mutants

Martin Ludlow | University of Veterinary Medicine Hannover Foundation, Hannover, Germany (15min)

Trimerization of the RSV Fusion protein leads to a high energy prefusion state, or why trimerizing is destabilizing RSV F

Johannes Langedijk | Janssen Vaccines & Prevention, The Netherlands (15min)

The respiratory syncytial virus attachment glycoprotein is altered when produced in primary human bronchial epithelial cultures, reducing its infectivity for cell lines

Tiffany King | The Ohio State University / Nationwide Childrens Hospital, USA (15min)

An unexpected encounter: RSV-NS1 interacts with a member of the mediator complex

Tessa Van Royen | VIB-UGent Center for Medical Biotechnology, Ghent University, Belgium (15min)

15 February RSV Pathogenesis and Immunity

3pm (GMT) Chair: Dr Lindsay Broadbent, Queens University Belfast, UK

VIEW WEBINAR RECORDING

Keynote Presentation:

An integrated view of susceptibility and resistance to RSV disease

Prof Peter Openshaw

Department of Experimental Medicine

Imperial College London, UK

(30 min presentation - includes 5 min for Q&A)

Localization of Respiratory Syncytial Virus (RSV) Antigen in Bronchiolar Epithelium

Mark Ackermann | LambCure LLC and Oregon State University, USA (15min)

Influenza Virus Inhibits RSV Infection via a Two-wave Expression of IFIT Proteins

Michal Mandelboim | Sheba Medical Center, Ramat Gan, Israel (15min)

Characterizing RSV Immunity on Mucosal Surfaces Following Natural Infection

Peter F. Wright | Geisel School of Medicine at Dartmouth, Hanover, USA (15min)

Presented by co-author Meave Otieno

Immunological impact of age in an experimental RSV challenge model in elderly humans

Stephanie Ascough | Imperial College London, UK (15min)

22 February RSV Vaccines and Therapies

3pm (GMT) Chair: Dr Simon B. Drysdale, St George's Hospital, London, UK

VIEW WEBINAR RECORDING

Keynote Presentation:

How RSV Biology Informed COVID-19 Vaccine Development

Dr Barney S. Graham

Deputy Director

Vaccine Research Center

National Institute of Allergy and Infectious Diseases, USA

(30 min presentation - includes 5 min for Q&A)

A Single-cycle Live RSV Vaccine Expressing Prefusion F Protein

Pramila Lamichhane | Oklahoma State University, USA (webinar recording not available at this time)

Phase 1/2a Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Seropositive Toddlers Aged 12 -24 Months

Matthew Snape | University of Oxford, UK (15min)

The Sensitivity of Palivizumab Cost-effectiveness in Mali to Case Fatality Estimates
Amanda Driscoll | University of Maryland, Baltimore, USA (15min)

The Flavonoid Cyanidin Shows Antiviral and Immunomodulatory Properties Against RSV, in Vitro and in Vivo

Carlos Bueno | Universidad de Buenos Aires, Argentina (15min)

Save

isirv

Font Size

SCREEN

Profile

Direction

Menu Style